Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

Company's belief that the supplemental data to be submitted in the amended NDA will overcome the need for additional trials, the review of the submissions for marketing approval of L-MTP-PE by the FDA and the EMEA, and the Company's goal of making L-MTP-PE available to patients as quickly as possible. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE by the first quarter of 2008, if at all, the possibility that such data will not support the benefit of L-MTP-PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, although the FDA is not bound by the decision of any advisory panel, the possible negative impact that the opinion of the FDA's Oncologic Drugs Advisory Committee that the results of the Company's Phase 3 trial do not provide substantial evidence of effectiveness of L-MTP-PE in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy would have upon the determination by the FDA whether to approve the marketing application for L- MTP-PE, which would have a material and adverse affect on IDM's business, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Ph
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
(Date:10/30/2014)... N.J. , Oct. 30, 2014  Regado Biosciences, ... it will hold a conference call and live audio ... EST to discuss its third quarter 2014 financial results. ... conference call by dialing (888) 347-1165 for domestic callers ... will be webcast live under the investor relations section ...
(Date:10/30/2014)... The severe flooding that devastated a wide swath of ... the bridges, roads and other infrastructure had been upgraded ... University of Colorado Denver. , "People need to understand ... PhD, associate professor of structural engineering at the CU ... author the study. "There is an assumption that a ...
(Date:10/27/2014)... October 27, 2014 The new ... Type (High & Medium), Sub-type (Primary & Secondary), ... Infrastructure & Transportation & Power Generation) - Trends ... GIS market with analysis and forecasting of the ... Data Tables with 52 Figures spread through 146 ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... BioTechnologies, Inc. (TriLink) and Lucigen Corporation (Lucigen) announced today ... for the use of TriLink,s CleanAmp™ dNTPs in Lucigen,s ... CleanAmp™ dNTPs are an innovative approach to Hot Start ... PCR assay with CleanAmp™ dNTPs, a Hot Start reaction ...
... DIEGO, July 28, 2011 Verenium Corporation (NASDAQ: ... commercialization of high-performance industrial enzyme solutions, today announced that ... its 5.5% Notes and approximately $3 million in principal ... very pleased to have taken another important step toward ...
... July 28, 2011 United Therapeutics Corporation (NASDAQ: ... ended June 30, 2011. "I,m pleased with the ... as the very good operating results we achieved," remarked Martine ... remain on track to reach our 2011 forecast for revenues ...
Cached Biology Technology:TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation 2Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 7
(Date:10/28/2014)... National University of Singapore (NUS) have discovered a new ... laying direct developing eggs in live bamboo with narrow ... bush frog ( Raorchestes chalazodes ). This critically ... known to adopt this novel reproductive strategy. The findings ... Biological Journal of the Linnean Society , in October ...
(Date:10/28/2014)... juices are associated with a lower risk of developing ... of East Anglia (UEA). , Research published today ... flavanones (both subclasses of dietary flavonoids) significantly decrease their ... of cancer death among women. , The research ... between 25 and 55 for more than three decades. ...
(Date:10/27/2014)... German . ... via electrical signals, they communicate with each other at ... substances, the neurotransmitters, are stored in vesicles at the ... vesicles fuse with the cell membrane and release their ... synapses always have some readily releasable vesicles on standby. ...
Breaking Biology News(10 mins):NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2Synapses always on the starting blocks 2Synapses always on the starting blocks 3
... they know to fear the scent of a predator. But how ... cat is nearby? It,s a complex process that starts ... noses. But until now it wasn,t clear exactly how these scent ... a study to be published in Nature (available online ...
... is relatively common to come across petrol stations surrounded by ... Murcia (UM) have studied the effects of contamination at petrol ... noted in buildings less than 100 metres from the service ... which increases the risk of cancer have been recorded ...
... It,s the champagne of the cheese world and the ... like Stilton are literally under the microscope in a quest ... of Nottingham and The University of Northampton are working with ... distinctive taste, texture and smell. The scientists hope to ...
Cached Biology News:The brain knows what the nose smells, but how? Stanford researchers trace the answer 2The brain knows what the nose smells, but how? Stanford researchers trace the answer 3Petrol stations pollute their immediate surroundings 2The quest for the ultimate blue cheese 2
... Power Supply, 1. 300 V, 400 ... constant current modes.Single-unit increments in settings ... for submarine, mini vertical, and standard ... semidry and mini tank blotting applications. ...
B3-1...
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Normal sheep serum collected from healthy normal sheep...
Biology Products: